Biopharmaceutical benchmarks: Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)831-833
Number of pages3
JournalNature Biotechnology
Volume18
Issue number8
DOIs
Publication statusPublished - 2000

Cite this